MCID: PPL007
MIFTS: 44

Papillary Serous Adenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Papillary Serous Adenocarcinoma

MalaCards integrated aliases for Papillary Serous Adenocarcinoma:

Name: Papillary Serous Adenocarcinoma 12 15
Serous Surface Papillary Carcinoma 12 74
Micropapillary Serous Carcinoma 12 17
Papillary Serous Cystadenocarcinoma 74
Papillary Serous Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2632
SNOMED-CT 69 15674004 90282004

Summaries for Papillary Serous Adenocarcinoma

Disease Ontology : 12 A papillary adenocarcinoma that derives from epithelial cells originating in glandular tissue, which form complex papillary structures with psammoma bodies.

MalaCards based summary : Papillary Serous Adenocarcinoma, also known as serous surface papillary carcinoma, is related to primary peritoneal carcinoma and uterine corpus serous adenocarcinoma. An important gene associated with Papillary Serous Adenocarcinoma is KRT7 (Keratin 7), and among its related pathways/superpathways are Hepatitis C and Hepatocellular Carcinoma and Integrated Cancer Pathway. The drugs Epirubicin and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include ovary, breast and liver, and related phenotypes are cellular and behavior/neurological

Related Diseases for Papillary Serous Adenocarcinoma

Diseases related to Papillary Serous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 246)
# Related Disease Score Top Affiliating Genes
1 primary peritoneal carcinoma 33.0 BRCA1 PGR TP53
2 uterine corpus serous adenocarcinoma 32.5 BRCA1 TP53
3 bilateral breast cancer 30.2 BRCA1 PGR
4 large cell neuroendocrine carcinoma 29.9 KRT20 KRT7 NKX2-1
5 mesothelioma, malignant 29.8 KRT20 KRT7 NKX2-1
6 carcinosarcoma 29.7 KRT7 PGR TP53
7 endometrial cancer 29.7 BRCA1 KRT7 PGR TP53
8 endometrial adenocarcinoma 29.6 KRT7 PGR TP53
9 endocervical adenocarcinoma 29.5 KRT20 KRT7 TP53
10 papillary carcinoma 29.5 KRT20 KRT7 NKX2-1 PGR
11 transitional cell carcinoma 29.5 KRT20 KRT7 TP53
12 ovarian cancer 1 29.4 BRCA1 KRT7 TP53
13 in situ carcinoma 29.4 BRCA1 PGR TP53
14 cervical adenocarcinoma 29.2 KRT20 KRT7 PGR TP53
15 small cell carcinoma 29.2 KRT20 KRT7 NKX2-1 TP53
16 ovarian cancer 29.2 BRCA1 KRT7 PGR TP53
17 ovary papillary carcinoma 11.5
18 adenocarcinoma 10.7
19 sweat gland disease 10.3 KRT7 PGR
20 sex cord-gonadal stromal tumor 10.3 KRT7 PGR
21 spindle cell carcinoma 10.3 KRT7 PGR
22 breast secretory carcinoma 10.3 KRT7 PGR
23 atypical choroid plexus papilloma 10.3 KRT7 NKX2-1
24 large cell carcinoma 10.3 KRT7 NKX2-1
25 cavernous hemangioma 10.3 KRT7 NKX2-1
26 eccrine papillary adenocarcinoma 10.3 KRT7 PGR
27 polycystic liver disease 1 with or without kidney cysts 10.3 KRT20 KRT7
28 immune system organ benign neoplasm 10.3 KRT20 KRT7
29 oncocytic breast carcinoma 10.3 KRT7 PGR
30 small intestine cancer 10.3 KRT20 KRT7
31 pericardium cancer 10.3 KRT7 PTGER4
32 thymus lipoma 10.3 KRT20 KRT7
33 ovarian brenner tumor 10.3 KRT20 KRT7
34 prostatic acinar adenocarcinoma 10.3 KRT20 KRT7
35 cecum adenocarcinoma 10.3 KRT20 KRT7
36 signet ring cell adenocarcinoma 10.3 KRT20 KRT7
37 mucinous cystadenocarcinoma 10.3 KRT20 KRT7
38 clear cell adenocarcinoma 10.3 KRT20 KRT7
39 adenocarcinoma in situ 10.3 KRT20 KRT7
40 cystadenofibroma 10.3 KRT20 KRT7
41 ovarian mucinous neoplasm 10.3 KRT20 KRT7
42 cystitis cystica 10.3 KRT20 KRT7
43 pericardial mesothelioma 10.3 KRT7 PTGER4
44 intestinal obstruction 10.3 KRT20 KRT7
45 cribriform carcinoma 10.3 KRT7 PGR
46 solid adenocarcinoma with mucin production 10.3 KRT7 NKX2-1
47 benign metastasizing leiomyoma 10.3 KRT7 PGR
48 ovarian germ cell teratoma 10.3 KRT7 NKX2-1
49 adenoid basal cell carcinoma 10.2 KRT7 PGR
50 tubular adenocarcinoma 10.2 KRT20 PGR

Graphical network of the top 20 diseases related to Papillary Serous Adenocarcinoma:



Diseases related to Papillary Serous Adenocarcinoma

Symptoms & Phenotypes for Papillary Serous Adenocarcinoma

MGI Mouse Phenotypes related to Papillary Serous Adenocarcinoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.87 BRCA1 KRT7 NKX2-1 PGR PTGER4 STK36
2 behavior/neurological MP:0005386 9.85 BRCA1 NKX2-1 PGR PTGER4 STK36 TP53
3 homeostasis/metabolism MP:0005376 9.8 BRCA1 KRT7 NKX2-1 PGR PTGER4 STK36
4 neoplasm MP:0002006 9.55 BRCA1 NKX2-1 PGR PTGER4 TP53
5 respiratory system MP:0005388 9.35 BRCA1 NKX2-1 PTGER4 STK36 TP53
6 skeleton MP:0005390 9.1 BRCA1 NKX2-1 PGR PTGER4 STK36 TP53

Drugs & Therapeutics for Papillary Serous Adenocarcinoma

Drugs for Papillary Serous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 101)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epirubicin Approved Phase 3 56420-45-2 41867
2
Cisplatin Approved Phase 3,Phase 2 15663-27-1 441203 84093 2767
3
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
5
Everolimus Approved Phase 2, Phase 3,Phase 1 159351-69-6 6442177 70789204
6
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
7
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1 53123-88-9 46835353 6436030 5284616
8
Letrozole Approved, Investigational Phase 2, Phase 3,Phase 3 112809-51-5 3902
9
Sodium Citrate Approved, Investigational Phase 2, Phase 3 68-04-2
10
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
11
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
12
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60700
13
Calcium Approved, Nutraceutical Phase 2, Phase 3 7440-70-2 271
14
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
15
Doxil Approved June 1999 Phase 3,Phase 2 31703
16 Hormones Phase 2, Phase 3,Phase 3
17 Antimitotic Agents Phase 2, Phase 3,Phase 1
18 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
19 Topoisomerase Inhibitors Phase 3,Phase 2
20 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
21 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
22 Hormone Antagonists Phase 2, Phase 3,Phase 3
23 Immunologic Factors Phase 2, Phase 3,Phase 1
24 Antifungal Agents Phase 2, Phase 3,Phase 1
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 3
26 Anti-Infective Agents Phase 2, Phase 3,Phase 1
27 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
28 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 1
29 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 1
30 Antineoplastic Agents, Hormonal Phase 2, Phase 3
31 Estrogens Phase 2, Phase 3,Phase 3
32 Aromatase Inhibitors Phase 2, Phase 3,Phase 3
33 Estrogen Receptor Antagonists Phase 2, Phase 3,Phase 3
34 Estrogen Antagonists Phase 2, Phase 3,Phase 3
35 Steroid Synthesis Inhibitors Phase 2, Phase 3,Phase 3
36 Chelating Agents Phase 2, Phase 3
37 Bone Density Conservation Agents Phase 2, Phase 3
38 Estrogen Receptor Modulators Phase 2, Phase 3
39 Selective Estrogen Receptor Modulators Phase 2, Phase 3
40 Citrate Phase 2, Phase 3
41 topoisomerase I inhibitors Phase 2, Phase 3
42 Calcium, Dietary Phase 2, Phase 3
43 Anticoagulants Phase 2, Phase 3
44
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
45
Carboplatin Approved Phase 2,Phase 1 41575-94-4 38904 10339178 498142
46
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
47
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
48
Histamine Approved, Investigational Phase 2 51-45-6 774
49
Cimetidine Approved, Investigational Phase 2 51481-61-9 2756
50
Promethazine Approved, Investigational Phase 2 60-87-7 4927

Interventional clinical trials:

(show all 28)
# Name Status NCT ID Phase Drugs
1 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
2 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
3 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
4 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
5 Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Active, not recruiting NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
6 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Active, not recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen Citrate;Topotecan Hydrochloride;Trametinib
7 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Active, not recruiting NCT01672892 Phase 3
8 Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Unknown status NCT00003560 Phase 2 carboplatin;docetaxel
9 Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma Completed NCT00506779 Phase 1, Phase 2 Imatinib Mesylate;Paclitaxel
10 Papillary Serous Carcinoma of the Endometrium Completed NCT00515073 Phase 2 Paclitaxel;Dexamethasone;Cimetidine;Diphenhydramine
11 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
12 Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer Completed NCT00022620 Phase 2 paclitaxel
13 Uterine Papillary Serous Cancer (UPSC) Trial Completed NCT00147680 Phase 2 Paclitaxel, Carboplatin
14 Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer Completed NCT00052312 Phase 2 cisplatin;doxorubicin hydrochloride;paclitaxel
15 Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00025467 Phase 2 thalidomide
16 Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus
17 Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
18 Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer Completed NCT00664781 Phase 2 rucaparib (CO-338; formally AG-014699 or PF-01367338)
19 Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma Terminated NCT00653328 Phase 2 atrasentan hydrochloride;doxil
20 A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers Terminated NCT00231829 Phase 2 Celecoxib
21 Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors Completed NCT01198184 Phase 1 temsirolimus;gamma-secretase/Notch signalling pathway inhibitor RO4929097
22 Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Withdrawn NCT02050009 Phase 1 metformin hydrochloride;carboplatin;paclitaxel
23 Role of Biomarkers in Endometrial Cancer Recurrence in Samples From Patients With Stage II, Stage III, or Stage IV Endometrial Cancer Unknown status NCT01150682
24 Endometrial Cancer and Fractalkine-receptor Axis of Fractalkine Completed NCT02774395
25 Collection of Tissue Samples From Patients With Stage III or Stage IV Ovarian Epithelial Cancer Completed NCT01096394
26 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704
27 French National Registry of Rare Peritoneal Surface Malignancies Active, not recruiting NCT02834169
28 Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer Not yet recruiting NCT01344837

Search NIH Clinical Center for Papillary Serous Adenocarcinoma

Genetic Tests for Papillary Serous Adenocarcinoma

Anatomical Context for Papillary Serous Adenocarcinoma

MalaCards organs/tissues related to Papillary Serous Adenocarcinoma:

42
Ovary, Breast, Liver, Bone, Lymph Node, Cervix, Brain

Publications for Papillary Serous Adenocarcinoma

Articles related to Papillary Serous Adenocarcinoma:

(show all 46)
# Title Authors Year
1
Long-term survival of high-grade primary peritoneal papillary serous adenocarcinoma: a case report and literature review. ( 28399919 )
2017
2
Filarial worm residing in ovarian papillary serous adenocarcinoma-A rare case report. ( 27444355 )
2016
3
Overexpression of annexin A4 is associated with chemoresistance in papillary serous adenocarcinoma of the ovary. ( 23290009 )
2013
4
Multiple brain metastases in a patient with uterine papillary serous adenocarcinoma: Treatment options for this rarely seen metastatic brain tumor. ( 24032086 )
2013
5
Malignant mixed mullerian tumor of endometrium coexisting with bilateral papillary serous adenocarcinoma of fallopian tube: a rare case report. ( 24293882 )
2012
6
Papillary-serous adenocarcinoma of the uterine cervix during tamoxifen therapy after bilateral breast cancer. ( 23155282 )
2012
7
F-18 fluoride uptake in calcified extraosseous metastases from ovarian papillary serous adenocarcinoma. ( 22157054 )
2012
8
Papillary serous adenocarcinoma of the uterine cervix: a case report. ( 21614930 )
2011
9
Acute gastric outlet obstruction secondary to papillary serous adenocarcinoma of the endometrium with peritoneal psammomatous implants: a case report. ( 19132421 )
2010
10
Successful Treatment of Primary Vaginal Papillary Serous Adenocarcinoma Using Chemoradiation Followed by Brachytherapy. ( 20740170 )
2009
11
99mTc-MDP and 18F-FDG uptake in calcified metastatic lesions from ovarian papillary serous adenocarcinoma. ( 19936349 )
2009
12
Malignant pericardial tamponade secondary to papillary serous adenocarcinoma of the ovary. ( 17491236 )
2007
13
Pulmonary papillary serous adenocarcinoma with intraperitoneal and ovarian tumors: identification of primary site. A case report. ( 16515596 )
2006
14
Establishment and characterization of a cell line derived from a human serous surface papillary carcinoma of the ovary. ( 17257376 )
2006
15
A long-term survivor of repeated inguinal nodes recurrence of papillary serous adenocarcinoma of CUP: case report. ( 16930493 )
2006
16
Serous surface papillary carcinoma of the peritoneum: clinical, radiologic, and pathologic findings in 11 patients. ( 15385282 )
2004
17
Establishment and characterization of two cell lines (HEC-155, HEC-180) derived from uterine papillary serous adenocarcinoma. ( 15285295 )
2004
18
Papillary serous adenocarcinoma of the endometrium: CT-pathologic correlation. ( 15150003 )
2004
19
CT features of serous surface papillary carcinoma of the ovary. ( 15547217 )
2004
20
Weekly topotecan in a heavily pretreated patient with peritoneal papillary serous adenocarcinoma. ( 15228430 )
2004
21
Papillary serous adenocarcinoma of the ovary diagnosed after malignant pericardial tamponade and embolic stroke. ( 11855887 )
2002
22
Cerebellar metastasis from papillary serous adenocarcinoma of the ovary mimicking MAcniA"re's disease. A case report. ( 11304872 )
2001
23
Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? ( 11104623 )
2000
24
Papillary serous adenocarcinoma of the endocervix: A rare neoplasm. Immunohistochemical profile. ( 11240696 )
2000
25
The combination paclitaxel, carboplatin and megestrol acetate is effective in women with recurrent uterine papillary serous adenocarcinoma. ( 10422674 )
1999
26
Supradiaphragmatic manifestations of papillary serous adenocarcinoma of the ovary. ( 10580766 )
1999
27
Multiple nodular metastases in mesenteric panniculitis by uterine papillary serous adenocarcinoma (UPSC): CT appearance of a case. ( 10416083 )
1999
28
Cytologic features of papillary serous adenocarcinoma of the uterine cervix. ( 9126137 )
1997
29
Radiological findings in serous surface papillary carcinoma of the ovary. Case reports. ( 9332242 )
1997
30
Serous surface papillary carcinoma of the ovary metastatic to a cervical polyp. A case report. ( 8693902 )
1996
31
Serous surface papillary carcinoma. ( 8654470 )
1996
32
Varieties of serous surface papillary carcinoma of the peritoneum in northern Germany: a thirty-year autopsy study. ( 8598333 )
1995
33
Histologic characterization of uterine papillary serous adenocarcinoma. ( 7705679 )
1995
34
Systemic lymphadenopathy as the primary symptom of serous surface papillary carcinoma of the ovary. ( 7622114 )
1995
35
Uterine papillary serous adenocarcinoma. A 10-case study of p53 and c-erbB-2 expression and DNA content. ( 7915964 )
1994
36
Ovarian involvement by serous surface papillary carcinoma. ( 8005732 )
1994
37
Papillary serous adenocarcinoma of the endometrium: a clinicopathologic study of 19 cases. ( 1634141 )
1992
38
Papillary serous adenocarcinoma of the uterine cervix: a report of three cases. ( 1495949 )
1992
39
Invasive papillary serous adenocarcinoma of the endocervix in pregnancy; a case report. ( 1855609 )
1991
40
Primary peritoneal papillary serous adenocarcinoma: clinical and management aspects. ( 2013445 )
1991
41
Hyperamylasemia associated with progression of a serous surface papillary carcinoma. ( 1690681 )
1990
42
Serous surface papillary carcinoma. A clinicopathologic study of 10 cases and comparison with stage III-IV ovarian serous carcinoma. ( 3189692 )
1988
43
Papillary serous adenocarcinoma of the endometrium. ( 3960439 )
1986
44
Serous surface papillary carcinoma of the ovary: a clinical, pathologic, ultrastructural, and immunohistochemical study of 11 cases. ( 2581219 )
1985
45
Serous surface papillary carcinoma of the ovary: a clinicopathologic study of 16 cases. ( 7185762 )
1982
46
Papillary serous adenocarcinoma. ( 18870241 )
1948

Variations for Papillary Serous Adenocarcinoma

Expression for Papillary Serous Adenocarcinoma

Search GEO for disease gene expression data for Papillary Serous Adenocarcinoma.

Pathways for Papillary Serous Adenocarcinoma

Pathways related to Papillary Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.11 BRCA1 TP53
2 11.03 BRCA1 TP53
3 10.97 BRCA1 TP53
4 10.76 BRCA1 TP53
5 10.65 BRCA1 TP53
6 10.42 BRCA1 TP53
7 9.9 BRCA1 TP53

GO Terms for Papillary Serous Adenocarcinoma

Biological processes related to Papillary Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell cycle arrest GO:0071158 8.96 BRCA1 TP53
2 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.62 BRCA1 TP53

Molecular functions related to Papillary Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription regulatory region DNA binding GO:0044212 9.13 BRCA1 NKX2-1 TP53
2 enzyme binding GO:0019899 8.92 BRCA1 NKX2-1 PGR TP53

Sources for Papillary Serous Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....